Skip to main content

Table 2 Expression of ATP1A1 mRNA (2−CT) in 6 cell lines (sensitive and resistant (-R) to MAPKi) and IC50 for bufalin in these cell lines

From: ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy

Lines

ATP1A1 mRNA

Ic50 bufalin (nM)

HBL

0.000063

2.10

HBL-R

0.000078

1.20

MM074

0.000034

3.40

MM074-R

0.000031

2.40

MM161

0.000005

9.10

MM161-R

0.000022

9.60

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us